Target Name: TEN1-CDK3
NCBI ID: G100529145
Other Name(s): C17orf106-CDK3 | TEN1-CDK3 readthrough (non-protein coding) | TEN1 | TEN1-CDK3 readthrough (NMD candidate) | C17orf106

TEN1-CDK3: A Potential Drug Target and Biomarker

TEN1-CDK3, a gene located on chromosome 16, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its unique expression pattern and biological significance have drawn significant interest from researchers, and its potential as a drug target have been evaluated in various studies.

The discovery of TEN1-CDK3

TEN1-CDK3 was first identified in the course of a genomic study using transcriptome sequencing (RNA-seq) technology. The study revealed that the gene was highly expressed in various tissues and organs, including brain, heart, muscle, and skin, but was not expressed in the liver or other organs. The gene has since been verified by RNA-seq and gene expression studies.

The biological significance of TEN1-CDK3

TEN1-CDK3 is involved in various biological processes that are crucial for human health and development. One of its key functions is that of a regulator of cell adhesion and migration. This gene has been shown to be involved in the development and maintenance of neural cell migration, which is critical for the formation of functional neural circuits in the brain.

In addition to its role in cell adhesion and migration, TEN1-CDK3 is also involved in the regulation of cell survival and proliferation. Studies have shown that the gene is involved in the regulation of cell cycle progression, and that it plays a role in the regulation of apoptosis, which is a critical mechanism for cell death and removal in cancer cells.

The potential as a drug target

The potential of TEN1-CDK3 as a drug target is based on its involvement in various biological processes that are crucial for human health and development. Its involvement in cell adhesion, migration, and survival have led to the conclusion that it may be a useful target for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the key advantages of TEN1-CDK3 as a drug target is its expression pattern in various tissues and organs, which makes it easier to identify potential drug candidates. Studies have shown that TEN1-CDK3 is expressed in various tissues, including brain, heart, muscle, and skin, and is not expressed in the liver or other organs. This makes it a potential target for drugs that can be administered directly to these tissues without the need for systemic exposure.

Another advantage of TEN1-CDK3 as a drug target is its potential to target a range of diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its involvement in cell adhesion, migration, and survival have led to the conclusion that it may be a useful target for the treatment of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

The role of TEN1-CDK3 as a biomarker

In addition to its potential as a drug target, TEN1-CDK3 has also been identified as a potential biomarker for various diseases. Its expression pattern has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases.

One of the key advantages of TEN1-CDK3 as a biomarker is its potential to be used as a diagnostic tool for various diseases. Its expression pattern has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. This makes it a potential diagnostic tool for these diseases, and has led to the conclusion that it may be useful in the development of personalized medicine.

Another advantage of TEN1-CDK3 as a biomarker is its potential to be used as a target for drugs that can

Protein Name: TEN1-CDK3 Readthrough (NMD Candidate)

More Common Targets

Teneurin | TENM1 | TENM2 | TENM2-AS1 | TENM3 | TENM3-AS1 | TENM4 | TENT2 | TENT4A | TENT4B | TENT5A | TENT5B | TENT5C | TENT5C-DT | TENT5D | TEP1 | TEPP | TEPSIN | TERB1 | TERB2 | TERC | TERF1 | TERF1P3 | TERF2 | TERF2IP | TERLR1 | TERT | TES | TESC | TESK1 | TESK2 | TESMIN | TESPA1 | TET1 | TET2 | TET2-AS1 | TET3 | Tetraspanin | TEX10 | TEX101 | TEX11 | TEX12 | TEX13A | TEX13B | TEX13C | TEX14 | TEX15 | TEX19 | TEX2 | TEX21P | TEX22 | TEX26 | TEX261 | TEX264 | TEX28 | TEX29 | TEX30 | TEX33 | TEX35 | TEX36 | TEX36-AS1 | TEX37 | TEX38 | TEX41 | TEX43 | TEX44 | TEX45 | TEX46 | TEX47 | TEX48 | TEX49 | TEX50 | TEX52 | TEX53 | TEX55 | TEX56P | TEX9 | TF | TFAM | TFAMP1 | TFAP2A | TFAP2A-AS1 | TFAP2A-AS2 | TFAP2B | TFAP2C | TFAP2D | TFAP2E | TFAP4 | TFB1M | TFB2M | TFCP2 | TFCP2L1 | TFDP1 | TFDP1P2 | TFDP2 | TFDP3 | TFE3 | TFEB | TFEC | TFF1